• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypoxia Inducible Factor 1 Alpha-Pipeline Review H1 2017

    Hypoxia Inducible Factor 1 Alpha-Pipeline Review H1 2017

    • Report Code ID: RW0001834454
    • Category Pharmaceuticals
    • No. of Pages 79
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H1 2017

    Summary

    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H1 2017, outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Hypoxia-inducible factor 1-alpha is a subunit of a heterodimeric transcription factor encoded by the HIF1A gene. It plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It activates the transcription of erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor and HILPDA under hypoxia condition. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Cardiovascular, Dermatology, Metabolic Disorders and Ophthalmology which include indications Hepatocellular Carcinoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Breast Cancer, Diabetic Foot Ulcers, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM) , Graft Versus Host Disease (GVHD) , Ischemia, Lung Cancer, Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease) , Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Peritoneal Cancer, Rectal Cancer, Rheumatoid Arthritis, Small-Cell Lung Cancer and Wounds.

    Furthermore, this report also reviewsalso reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
    - The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development
    CASI Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    InterMed Discovery GmbH
    NewLink Genetics Corp
    OncoImmune Inc
    Peloton Therapeutics Inc
    RXi Pharmaceuticals Corp
    Sorrento Therapeutics Inc
    Vascular Biogenics Ltd
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles
    A-503451A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BC-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CASI-2ME2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CRLX-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Echinomycin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HS-1793 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMD-026259 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KCN-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MPT-0B098 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-6061 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit HIF-1 Alpha for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SR-16388 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TR-764 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VB-411 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products
    Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development Milestones
    Featured News & Press Releases
    Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting
    Aug 18, 2016: Cerulean Announces Reduction in Force
    Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma
    Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer
    Jun 22, 2016: Cerulean Announces Publication in Cancer Research
    Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology
    May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference
    May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA
    Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
    Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
    Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue
    Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting
    Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by CASI Pharmaceuticals Inc, H1 2017
    Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Pipeline by InterMed Discovery GmbH, H1 2017
    Pipeline by NewLink Genetics Corp, H1 2017
    Pipeline by OncoImmune Inc, H1 2017
    Pipeline by Peloton Therapeutics Inc, H1 2017
    Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Pipeline by Sorrento Therapeutics Inc, H1 2017
    Pipeline by Vascular Biogenics Ltd, H1 2017
    Dormant Products, H1 2017
    Dormant Products, H1 2017 (Contd..1) , H1 2017
    Dormant Products, H1 2017 (Contd..2) , H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    CASI Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    F. Hoffmann-La Roche Ltd
    InterMed Discovery GmbH
    NewLink Genetics Corp
    OncoImmune Inc
    Peloton Therapeutics Inc
    RXi Pharmaceuticals Corp
    Sorrento Therapeutics Inc
    Vascular Biogenics Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//hypoxia-inducible-factor-1-alpha-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hypoxia-inducible-factor-1-alpha-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hypoxia-inducible-factor-1-alpha-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments